Market closed
Astria Therapeutics/$ATXS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Astria Therapeutics
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
Ticker
$ATXS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
78
Website
ATXS Metrics
BasicAdvanced
$248M
-
-$1.68
0.69
-
Price and volume
Market cap
$248M
Beta
0.69
52-week high
$12.70
52-week low
$3.56
Average daily volume
476K
Financial strength
Current ratio
17.492
Quick ratio
17.152
Long term debt to equity
1.243
Total debt to equity
1.677
Management effectiveness
Return on assets (TTM)
-23.36%
Return on equity (TTM)
-33.52%
Valuation
Price to book
1.11
Price to tangible book (TTM)
1.11
Price to free cash flow (TTM)
-3.043
Growth
Earnings per share change (TTM)
-30.64%
3-year earnings per share growth (CAGR)
-59.13%
What the Analysts think about ATXS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Astria Therapeutics stock.
ATXS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ATXS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ATXS News
AllArticlesVideos
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·6 days ago
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·1 month ago
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Astria Therapeutics stock?
Astria Therapeutics (ATXS) has a market cap of $248M as of May 09, 2025.
What is the P/E ratio for Astria Therapeutics stock?
The price to earnings (P/E) ratio for Astria Therapeutics (ATXS) stock is 0 as of May 09, 2025.
Does Astria Therapeutics stock pay dividends?
No, Astria Therapeutics (ATXS) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next Astria Therapeutics dividend payment date?
Astria Therapeutics (ATXS) stock does not pay dividends to its shareholders.
What is the beta indicator for Astria Therapeutics?
Astria Therapeutics (ATXS) has a beta rating of 0.69. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.